Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
29,944,096
-
Share change
-
-22,602
-
Total reported value
-
$383,463,101
-
Put/Call ratio
-
49%
-
Price per share
-
$12.84
-
Number of holders
-
102
-
Value change
-
+$7,943,628
-
Number of buys
-
58
-
Number of sells
-
35
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2022
As of 30 Sep 2022,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,944,096 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, PICTET ASSET MANAGEMENT SA, HHLR ADVISORS, LTD., BAKER BROS. ADVISORS LP, Rubric Capital Management LP, Hudson Bay Capital Management LP, MILLENNIUM MANAGEMENT LLC, ArrowMark Colorado Holdings LLC, and GOLDMAN SACHS GROUP INC.
This page lists
102
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.